Panch.Organics Share Price & Earnings Call Analysis

Financials of Panch.Organics

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Panch.Organics

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +27.9629.5324.6323.7125.6131.2726.0527.1826.2428.3723.5625.3226.73
Expenses +22.2425.5819.7519.2820.7026.5421.6222.0521.7023.6019.8121.8222.95
Operating Profit5.723.954.884.434.914.734.435.134.544.773.753.503.78
OPM %20.46%13.38%19.81%18.68%19.17%15.13%17.01%18.87%17.30%16.81%15.92%13.82%14.14%
Other Income +0.011.170.101.011.220.130.740.700.960.000.660.641.06
Interest0.180.230.070.110.050.050.060.140.080.090.060.080.09
Depreciation0.310.640.380.410.390.560.540.560.580.510.560.580.60
Profit before tax5.244.254.534.925.694.254.575.134.844.173.793.484.15
Tax %25.19%30.12%25.17%25.20%25.13%34.59%24.95%26.12%24.17%23.98%25.07%25.00%11.33%
Net Profit +3.922.993.393.694.262.783.433.793.673.172.852.613.68
EPS in Rs3.332.542.883.133.622.112.602.882.792.412.161.982.79

Financials of Panch.Organics

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +393640404248504969103105107104
Expenses +35313433354142415683869088
Operating Profit456777991320191816
OPM %11%13%14%17%16%14%17%18%19%19%18%16%15%
Other Income +0000000001232
Interest1110100001000
Depreciation1111111112222
Profit before tax334556771119191816
Tax %35%32%27%36%29%29%28%31%27%26%27%24%
Net Profit +22334455814141412
EPS in Rs1.761.903.043.213.674.045.295.018.3311.9410.7110.479.34
Dividend Payout %14%13%17%16%14%12%0%20%18%7%7%8%

Financials of Panch.Organics

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital555555551012131313
Reserves12131619222530353784112121125
Borrowings +5757654446654
Other Liabilities +12811912912142221282429
Total Liabilities353337394444525874123159163171
Fixed Assets +8778776778141819
CWIP002222222461517
Investments0000000000300
Other Assets +282628303636444965111137131135
Total Assets353337394444525874123159163171

Financials of Panch.Organics

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +31313255-20104
Cash from Investing Activity +-1-1-2-2-1-1-2-1-0-34-7-16
Cash from Financing Activity +-20-11-2-2-1-2-13616-5
Net Cash Flow00-10-0013-2118-18
Free Cash Flow2-0-0-12143-3-4-0-12
CFO/OP88%46%69%45%79%63%73%85%5%28%82%48%

Financials of Panch.Organics

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days130142134138170137164140172137137119
Inventory Days124154155185185164186246237181211246
Days Payable1088010983124731111521588911488
Cash Conversion Cycle146216181240231229239235251230234276
Working Capital Days104136138137150155170167192173178204
ROCE %15%14%19%20%18%18%20%19%25%26%17%14%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd